Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development
News|Podcasts|August 13, 2025

ACT Brief Episode 3: Breaking Down Data Silos to Accelerate Clinical Trials

In this episode of the Applied Clinical Trials Brief, we spotlight a recent video interview with Luke Wilson of Thermo Fisher Scientific in which he shared insights on how data visibility, remote monitoring, and integrated systems can streamline inspections, improve patient safety, and keep decentralized trials compliant and on track.

This is the Applied Clinical Trials Brief—your fast track to the latest insights in clinical research operations. In under three minutes, we’ll recap top stories, highlight expert interviews, and keep you current on what’s moving the industry. Let’s get into it.

On this episode, we’re sharing highlights from a recent conversation with Luke Wilson, senior director for biotech and pharma services at Thermo Fisher Scientific, on how data visibility, integrated systems, and remote monitoring are transforming clinical trial operations.

Wilson began by underscoring why data visibility is now a critical driver for biotechs. With aggressive timelines and tight budgets, sponsors need actionable data from across the supply chain to make informed, real-time decisions that protect patients and keep trials on track.

He also highlighted the role of remote monitoring in accelerating decision-making. By maintaining a live connection to sites, sponsors can track patient safety more closely, improve trial outcomes, and reduce burdens on site staff—especially when paired with advanced devices and digital platforms.

Integrated systems, Wilson explained, are key to staying inspection-ready in an era of evolving regulatory expectations. Breaking down data silos ensures consistent capture and management, streamlining sponsor access and smoothing the path through FDA inspections.

When it comes to barriers to real-time oversight, Wilson pointed to data silos as the most persistent challenge. Overcoming them requires better system integration, along with built-in analytics and dashboards to deliver live insights that stakeholders can act on immediately.

Finally, for decentralized trials, Wilson stressed best practices such as unified data management platforms, clear SOPs, and strong governance and escalation pathways to maintain operational alignment and regulatory compliance throughout the trial lifecycle.

For more on this and other developments in clinical research, visit us at appliedclinicaltrialsonline.com. Thanks for listening to the Applied Clinical Trials Brief.


Related to this article

© photon_photo - © photon_photo - stock.adobe.com
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.